文献速递细菌感染、耐药与抗菌药物医院感染防控

土耳其SMART 2011-12:尿路与腹腔感染的病原体流行病学及药敏

Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

该研究基于SMART项目,在土耳其六家医院收集2011-2012年尿路感染(UTI)和腹腔感染(IAI)的革兰阴性病原体,比较医院获得性(HA)与社区获得性(CA)UTI及ICU与非ICU相关IAI的病原体分布、ESBL阳性率及药敏。结果显示大肠埃希菌最常见,HA UTI的ESBL阳性大肠埃希菌比例显著高于CA UTI,非ICU相关IAI高于ICU相关IAI;仅阿米卡星对UTI中≥90%病原体有活性,厄他培南、亚胺培南和阿米卡星对IAI中≥90%大肠埃希菌有活性,亚胺培南、阿米卡星和头孢西丁对≥90%肺炎克雷伯菌有活性。

要点

  • 大肠埃希菌是土耳其UTI和IAI最常见病原体。
  • HA UTI的ESBL阳性大肠埃希菌比例显著高于CA UTI。
  • 非ICU相关IAI的ESBL阳性大肠埃希菌比例高于ICU相关IAI。

核心结论

  • 大肠埃希菌仍是土耳其UTI和IAI的主要病原体,ESBL阳性率高且革兰阴性杆菌耐药普遍,尤其在HA UTI和ICU相关IAI中。

研究设计与样本

  • 基于SMART研究,2011-2012年土耳其六家医院收集UTI来源363株和IAI来源458株革兰阴性病原体,比较HA与CA UTI及ICU与非ICU相关IAI。

主要发现

  • 大肠埃希菌在HA UTI占40.2%,CA UTI占73.9%,ICU相关IAI占25.8%,非ICU相关IAI占43.3%。
  • ESBL阳性大肠埃希菌在HA UTI为50.5%,CA UTI为38.2%(P<0.001)。
  • ESBL阳性大肠埃希菌在非ICU相关IAI为52.5%,ICU相关IAI为29.2%(P=0.029)。

关键数值与推荐

  • UTI中仅阿米卡星对≥90%病原体有活性。
  • IAI中厄他培南、亚胺培南和阿米卡星对≥90%大肠埃希菌有活性。
  • IAI中亚胺培南、阿米卡星和头孢西丁对≥90%肺炎克雷伯菌有活性。

临床怎么用

  • 在土耳其,HA UTI和ICU相关IAI经验性治疗需考虑覆盖ESBL阳性菌,碳青霉烯类或阿米卡星可能提供最广抗菌活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the epidemiology and susceptibility of pathogens (including ESBL producers) from hospital-acquired (HA) versus community-acquired (CA) urinary tract infections (UTIs) and ICU- versus non-ICU-associated intra-abdominal infections (IAIs) in Turkey as a part of the SMART study. METHODS: : For this report, Gram-negative pathogens (363 from UTIs and 458 from IAIs) were collected in 2011 and 2012 at six hospitals in Turkey. HA versus CA UTIs and ICU- versus non-ICU-associated IAIs were compared for the species isolated, percentage of ESBL-positive isolates by species and susceptibility for overall and individual Gram-negative species. RESULTS: : Escherichia coli was the most common pathogen identified in HA (40.2%) and CA (73.9%) UTIs and ICU-associated (25.8%) and non-ICU-associated (43.3%) IAIs. The rate of ESBL-positive E. coli was significantly higher in HA than in CA UTIs (50.5% versus 38.2%, P < 0.001) and in non-ICU-associated than in ICU-associated IAIs (52.5% versus 29.2%, P = 0.029). Of the drugs studied, only amikacin was active against ≥90% of pathogens in UTIs, while ertapenem, imipenem and amikacin were active against ≥90% of E. coli ; and imipenem, amikacin and cefoxitin were active against ≥90% of Klebsiella pneumoniae in IAIs. CONCLUSIONS: Our findings demonstrated that E. coli continues to be the principal pathogen of UTIs and IAIs in Turkey. Along with a high rate of ESBL-positive isolates, high antimicrobial resistance among Gram-negative bacilli from either UTIs or IAIs was noted particularly in the case of HA UTIs and ICU-associated IAIs, with a higher likelihood of carbapenem- or amikacin-based therapy to provide the broadest activity against bacterial pathogens.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Koksal I, Yilmaz G, Unal S, et al. Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections. J Antimicrob Chemother. 2017. PMID: 28122913. doi:10.1093/jac/dkw574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。